Balyasny Asset Management
DNLI icon

Balyasny Asset Management’s Denali Therapeutics DNLI Stock Holding History

Balyasny Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,000
Closed -$767K – 2874
2022
Q3 		$767K Buy
+25,000
New +$813K ﹤0.01% 1898

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's DNLI Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Denali Therapeutics (DNLI) in Q1 2026: 195,108 shares worth $3.75M. The stake represents ﹤0.01% of the portfolio and ranks #1498 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in DNLI as recently as Q1 2025.

Balyasny Asset Management first reported a position in DNLI in Q2 2019 and has held it in 16 quarters since. The position peaked at $8.48M in Q4 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Balyasny Asset Management held 195,108 shares of Denali Therapeutics worth $3.75M as of Q1 2026.
  • Denali Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Denali Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1498 holding.
  • Balyasny Asset Management first reported a position in Denali Therapeutics in Q2 2019 and has held it in 16 quarters since.
  • Balyasny Asset Management's Denali Therapeutics position peaked at $8.48M in Q4 2024.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.